USD 2.52
(2.02%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 50.58 Million USD | 6.09% |
2022 | 47.68 Million USD | -6.2% |
2021 | 50.83 Million USD | 10.87% |
2020 | 45.84 Million USD | -12.85% |
2019 | 52.6 Million USD | -21.98% |
2018 | 67.43 Million USD | 0.77% |
2017 | 66.91 Million USD | 29.22% |
2016 | 51.78 Million USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 20.09 Million USD | 66.76% |
2024 Q1 | 12.05 Million USD | -8.73% |
2024 Q3 | 13.54 Million USD | -32.62% |
2023 Q2 | 13.24 Million USD | 18.92% |
2023 Q1 | 11.13 Million USD | 4.23% |
2023 FY | 50.58 Million USD | 6.09% |
2023 Q4 | 13.2 Million USD | 1.57% |
2023 Q3 | 13 Million USD | -1.8% |
2022 FY | 47.68 Million USD | -6.2% |
2022 Q1 | 12.27 Million USD | 10.76% |
2022 Q4 | 10.68 Million USD | -6.81% |
2022 Q3 | 11.46 Million USD | -13.58% |
2022 Q2 | 13.26 Million USD | 8.11% |
2021 FY | 50.83 Million USD | 10.87% |
2021 Q1 | 11.12 Million USD | 55.57% |
2021 Q2 | 15.34 Million USD | 37.97% |
2021 Q3 | 13.28 Million USD | -13.41% |
2021 Q4 | 11.07 Million USD | -16.63% |
2020 Q4 | 7.14 Million USD | -13.45% |
2020 Q2 | 21.67 Million USD | 147.29% |
2020 FY | 45.84 Million USD | -12.85% |
2020 Q1 | 8.76 Million USD | -46.62% |
2020 Q3 | 8.26 Million USD | -61.89% |
2019 Q2 | 11.12 Million USD | -11.98% |
2019 FY | 52.6 Million USD | -21.98% |
2019 Q4 | 16.41 Million USD | 32.22% |
2019 Q3 | 12.41 Million USD | 11.58% |
2019 Q1 | 12.64 Million USD | -24.85% |
2018 Q2 | 13.92 Million USD | -40.51% |
2018 FY | 67.43 Million USD | 0.77% |
2018 Q4 | 16.82 Million USD | 26.81% |
2018 Q3 | 13.26 Million USD | -4.75% |
2018 Q1 | 23.41 Million USD | 91.97% |
2017 Q2 | 11.14 Million USD | -32.21% |
2017 Q3 | 27.14 Million USD | 143.64% |
2017 Q1 | 16.43 Million USD | 0.0% |
2017 Q4 | 12.19 Million USD | -55.08% |
2017 FY | 66.91 Million USD | 29.22% |
2016 FY | 51.78 Million USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 566.76 Million USD | 91.075% |
Embecta Corp. | 1.12 Billion USD | 95.487% |
ANI Pharmaceuticals, Inc. | 486.81 Million USD | 89.609% |
Dynavax Technologies Corporation | 232.28 Million USD | 78.224% |
Esperion Therapeutics, Inc. | 116.33 Million USD | 56.519% |
Pacira BioSciences, Inc. | 674.97 Million USD | 92.506% |
PainReform Ltd. | - USD | -Infinity% |
Sunshine Biopharma, Inc. | 24.09 Million USD | -109.951% |
SCYNEXIS, Inc. | 140.14 Million USD | 63.906% |
China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -2522.923% |
Cosmos Health Inc. | 53.37 Million USD | 5.234% |
Journey Medical Corporation | 79.18 Million USD | 36.117% |
Sunshine Biopharma, Inc. | 24.09 Million USD | -109.951% |
Safety Shot Inc | 202.67 Thousand USD | -24858.307% |
Alpha Teknova, Inc. | 36.68 Million USD | -37.888% |
Intra-Cellular Therapies, Inc. | 464.37 Million USD | 89.107% |
Bright Green Corporation | 401.49 Thousand USD | -12498.788% |
Procaps Group, S.A. | 409.92 Million USD | 87.66% |
Theratechnologies Inc. | 81.76 Million USD | 38.135% |
Harrow Health, Inc. | 130.19 Million USD | 61.148% |
Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -297.197% |
Biofrontera Inc. | 34.07 Million USD | -48.464% |
DURECT Corporation | 8.54 Million USD | -491.752% |
Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 91.674% |
Cronos Group Inc. | 88.84 Million USD | 43.063% |
OptiNose, Inc. | 70.98 Million USD | 28.743% |
Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 88.575% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
RedHill Biopharma Ltd. | 6.51 Million USD | -676.626% |
Organogenesis Holdings Inc. | 433.14 Million USD | 88.322% |
Guardion Health Sciences, Inc. | 12.24 Million USD | -312.971% |
Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -27.888% |
Radius Health, Inc. | 2.88 Billion USD | 98.245% |
Universe Pharmaceuticals INC | 32.3 Million USD | -56.561% |
ProPhase Labs, Inc. | 44.38 Million USD | -13.967% |
Phibro Animal Health Corporation | 1.01 Billion USD | 95.03% |
Procaps Group S.A. | 409.92 Million USD | 87.66% |
Alvotech | 91.43 Million USD | 44.678% |
TherapeuticsMD, Inc. | 1.3 Million USD | -3785.023% |
Viatris Inc. | 15.42 Billion USD | 99.672% |
Rockwell Medical, Inc. | 83.61 Million USD | 39.503% |
Aytu BioPharma, Inc. | 81 Million USD | 37.553% |
SIGA Technologies, Inc. | 139.91 Million USD | 63.848% |
Tilray Brands, Inc. | 788.94 Million USD | 93.589% |
Lifecore Biomedical, Inc. | 128.26 Million USD | 60.562% |
Shineco, Inc. | 9.8 Million USD | -416.055% |
PetIQ, Inc. | 1.1 Billion USD | 95.41% |
Regencell Bioscience Holdings Limited | - USD | -Infinity% |
Incannex Healthcare Limited | 12 Thousand USD | -421425.0% |
Neurocrine Biosciences, Inc. | 1.88 Billion USD | 97.32% |
Alimera Sciences, Inc. | 80.75 Million USD | 37.362% |
Silver Spike Investment Corp. | 11.72 Million USD | -331.517% |
Assertio Holdings, Inc. | 152.06 Million USD | 66.737% |
Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Petros Pharmaceuticals, Inc. | 5.82 Million USD | -768.767% |
Clever Leaves Holdings Inc. | 17.41 Million USD | -190.423% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -4599.254% |
Avadel Pharmaceuticals plc | 27.96 Million USD | -80.893% |
Hempacco Co., Inc. | 4.04 Million USD | -1150.31% |
Talphera, Inc. | 651 Thousand USD | -7670.046% |
Alvotech | 91.43 Million USD | 44.678% |
Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 84.024% |
Lantheus Holdings, Inc. | 1.29 Billion USD | 96.098% |
Currenc Group, Inc. | 53.25 Million USD | 5.018% |
Kamada Ltd. | 144.75 Million USD | 65.057% |
Indivior PLC | 1.09 Billion USD | 95.372% |
Evoke Pharma, Inc. | 5.18 Million USD | -876.387% |
Flora Growth Corp. | 76.07 Million USD | 33.506% |
Cyclo Therapeutics, Inc. | 1.07 Million USD | -4599.254% |
Evolus, Inc. | 202.08 Million USD | 74.969% |
HUTCHMED (China) Limited | 837.99 Million USD | 93.964% |
Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 92.15% |
Akanda Corp. | 2.16 Million USD | -2241.749% |